Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H13ClN4O2S2.ClH |
Molecular Weight | 417.333 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.NCCC1=CN(C2=C1C=CC=C2)S(=O)(=O)C3=C(Cl)N=C4SC=CN34
InChI
InChIKey=YWNBHKWSECANPP-UHFFFAOYSA-N
InChI=1S/C15H13ClN4O2S2.ClH/c16-13-14(19-7-8-23-15(19)18-13)24(21,22)20-9-10(5-6-17)11-3-1-2-4-12(11)20;/h1-4,7-9H,5-6,17H2;1H
Molecular Formula | C15H13ClN4O2S2 |
Molecular Weight | 380.872 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
WAY-181187 is a high affinity and selective 5-HT6 agonist. It displays 60-fold selectivity over other 5-HT and monoamine receptors. WAY-181187 stimulates cAMP, ERK1/2 and Fyn kinase signaling pathway through serotonin receptor activation. WAY-181187 produced both antidepressant-like and anxiolytic-like effects in the animal model. It had been in phase I clinical trial for the treatment of anxiety disorders but this research has been discontinued.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3371 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17625499 |
2.2 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist. | 2007 Nov 15 |
|
Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466. | 2008 May |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17922111
Rat: 10 mg/kg
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17625499
In hippocampal slice sections, sodium azide (10 mM) treatment significantly increased glutamate (P = 0.0039) release compared with vehicle treatment.
Pretreatment of WAY-181187 (0.1–10 uM) significantly and dose-dependently attenuated sodium azide-stimulated increases but did not alter basal amino-acid levels in this in vitro system. P-values comparing doses of WAY-181187
to sodium azide were as follows: glutamate - 0.1 uM, P = 0.1032; 0.3 uM, P=0.0001; 1 uM, P = 0.0492; 3 uM, P=0.0001; 10 uM, P=0.0001.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:57:11 GMT 2023
by
admin
on
Fri Dec 15 15:57:11 GMT 2023
|
Record UNII |
XGK56C5380
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
554403-08-6
Created by
admin on Fri Dec 15 15:57:11 GMT 2023 , Edited by admin on Fri Dec 15 15:57:11 GMT 2023
|
PRIMARY | |||
|
22219735
Created by
admin on Fri Dec 15 15:57:11 GMT 2023 , Edited by admin on Fri Dec 15 15:57:11 GMT 2023
|
PRIMARY | |||
|
XGK56C5380
Created by
admin on Fri Dec 15 15:57:11 GMT 2023 , Edited by admin on Fri Dec 15 15:57:11 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |